Opinion|Videos|September 18, 2024
Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are the potential benefits of integrating PD-1 inhibitors into standard treatment protocols for NPC?
- What does the future look like for PD-1 Inhibitors in NPC?
Advertisement
Related to this article
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dive Into Key Data and Presentations From EHA 2026
4
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
5